top of page
Multiple Myeloma Clinical Trials - United Kingdom
NCT05572515
NCT05556616
NCT01838512
NCT05572515
1/33
Multiple Myeloma Clinical Trials Currently Recruiting
2022 - NCT05572515
Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
2022 - NCT05556616
Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
2022 - NCT05552222
Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
2022 - NCT05519085
Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1
2022 - NCT05461209
Phase 3: Talquetamab Vs Belantamab Mafodotin RRMM - (MonumenTAL-5)
2022 - NCT05455320
Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
2022 - NCT05372354
Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
2022 - NCT05243797
Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)
2021-NCT05050097
Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
2021 - NCT05160584
A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)
2021 - NCT05083169
Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
2021 - NCT05064358
Phase 2 - Alternative Dosing Regimens of Belantamab Mafodotin RRMM - (DREAMM 14)
2021 - NCT05020236
Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
2021 - NCT05014412
Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
2021 - NCT04975997
Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
2021 - NCT04923893
Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
2021 - NCT04855929
Phase 1: Safety and Therapeutic Activity of ANV419 in RRMM - ANV419-001
2021 - NCT04722146
Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
2020 - NCT04557150
Phase 1: Safety and Pharmacokinetics of Escalating Doses of RO7425781 RRMM Myeloma
2020 - NCT04557098
Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
2020 - NCT04484623
Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)
2020 - NCT04270409
Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
2019 - NCT04091126
Phase 1 - Belantamab Mafodotin + Standard of Care New Multiple Myeloma (DREAMM 9) NDMM
2019 - NCT04068597
Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies - RRMM Myeloma
2018 - NCT03761108
Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
bottom of page